More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm PPS a potential in the treatment of viral arthritis

Sep 6, 2016 at 11:12 PM EDT · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Sep 6, 2016 at 11:12 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/paradigm-pps-a-potential-in-the-treatment-of-viral-arthritis

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • Preliminary Final ReportAug 31, 2016
  • Paradigm PPS nasal spray to treat Allergic RhinitisAug 19, 2016
  • Shareholders UpdateJun 20, 2016
  • ASX Admission Market ReleaseJun 20, 2016
  • Paradigm Secures Key US PatentJun 20, 2016

Later from Paradigm Biopharmaceuticals

  • Preclinical study underpins efficacy of Paradigms RhinosulRSep 15, 2016
  • Paradigms Placement heavily oversubscribedOct 17, 2016
  • Appendix 4C - September 2016 quarterOct 28, 2016
  • Paradigms hay fever clinical trial cleared to commenceNov 21, 2016
  • Recruitment complete in Paradigms hay fever clinical trialJan 24, 2017
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer